Tdap Should Be Administered
For a child who received a tetanus-containing vaccine one year ago, you should administer Tdap (tetanus-diphtheria-acellular pertussis) rather than tetanus toxoid alone or Td, as current guidelines explicitly remove any minimum interval restrictions and prioritize pertussis protection. 1
Rationale for Tdap Over Other Options
No Interval Restriction
- The 2011 AAP and CDC guidelines explicitly removed the previous recommendation for caution regarding Tdap use within any interval after a tetanus- or diphtheria-containing vaccine. 1
- Tdap should be given when indicated regardless of the interval since the last tetanus- or diphtheria-containing vaccine. 1
- Clinical trials demonstrated no excess reactogenicity when Tdap is given within short intervals after other tetanus- or diphtheria-containing products, with excellent postmarketing safety data. 1
Safety of Short Intervals
- Research specifically evaluating intervals as short as 18 months found only minimal increases in local injection site reactions (maximum 8.6% increase in erythema, 10.3% in swelling) with no whole limb swelling, Arthus-like reactions, or serious adverse events. 2
- A mass vaccination campaign study confirmed that Tdap administration less than 2 years after previous tetanus vaccination showed non-inferior safety profiles with no significantly greater rates of moderate or severe injection site adverse events. 3
Pertussis Protection Priority
- The critical advantage of Tdap over Td or tetanus toxoid alone is the inclusion of acellular pertussis antigens, which provide protection against pertussis—a disease with significant morbidity in adolescents and adults. 1
- Tdap elicits robust immune responses to pertussis antigens that exceed (by 2.1 to 5.4 times) levels in infants following primary DTaP immunization. 4
- For children aged 7-10 years who were underimmunized with DTaP, a single dose of Tdap is specifically recommended. 1
FDA-Approved Dosing
Boostrix (Tdap) Specifications
- Approved for active booster immunization in individuals aged 10 years and older. 5
- May be administered for tetanus prophylaxis for wound management if at least 5 years have elapsed since previous tetanus toxoid-containing vaccine, though current guidelines support shorter intervals when otherwise indicated. 5
- Administered as a 0.5-mL intramuscular injection into the deltoid muscle. 5
When to Consider Alternatives
Contraindications to Tdap
- Severe allergic reaction (anaphylaxis) to any component or after previous dose of tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine. 5
- Encephalopathy within 7 days of previous pertussis antigen-containing vaccine not attributable to another cause. 5
- In these rare situations, Td would be the appropriate alternative. 1, 6
Arthus-Type Hypersensitivity
- If the child experienced an Arthus-type hypersensitivity reaction following a prior tetanus toxoid-containing vaccine, defer Tdap or other tetanus toxoid-containing vaccines for at least 10 years. 5
- This is an uncommon scenario but represents the primary situation where the one-year interval would matter clinically. 1
Clinical Considerations
Reactogenicity Profile
- Tdap demonstrates a similar overall safety profile to Td vaccine, with comparable rates of solicited local and systemic reactions and adverse events. 4, 7
- The incidence of grade 3 pain at injection site is non-inferior between Tdap and Td. 7
Tetanus Toxoid Alone
- Single-antigen tetanus toxoid is not preferred because it misses the opportunity to enhance diphtheria and pertussis protection. 6
- For wound management in patients 7 years and older, a preparation containing tetanus and diphtheria toxoids (Td or Tdap) is preferred over single-antigen tetanus toxoid. 6